BiotechTube

Human papillomavirus 9-valent vaccine, recombinant + human papillomavirus vaccine, recombinant

ApprovedRecruiting
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Papillomavirus Vaccines

Conditions

Papillomavirus Vaccines, Human Immunodeficiency Virus, Papillomavirus Infection, Serology, Cervical Intraepithelial Neoplasia, Anal Intraepithelial Neoplasia, Oral Cavity Infection

Trial Timeline

Nov 30, 2022 → Jun 1, 2026

NCT ID
NCT05266898

About Human papillomavirus 9-valent vaccine, recombinant + human papillomavirus vaccine, recombinant

Human papillomavirus 9-valent vaccine, recombinant + human papillomavirus vaccine, recombinant is a approved stage product being developed by Merck for Papillomavirus Vaccines. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05266898. Target conditions include Papillomavirus Vaccines, Human Immunodeficiency Virus, Papillomavirus Infection.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT05266898ApprovedRecruiting

Competing Products

20 competing products in Papillomavirus Vaccines

See all competitors
ProductCompanyStageHype Score
AAVLP-HPV + Placebo2A PharmaPhase 1
25
9vHPV vaccineMerckPhase 3
77
Human Papillomavirus 9-valent Vaccine, RecombinantMerckApproved
85
V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)MerckPhase 3
77
V503 + Comparator: Menactra™ (Concomitant) + Comparator: Adacel™ (Concomitant) + Comparator: Menactra™ (Non-Concomitant) + Comparator: Adacel™ (Non-concomitant)MerckPhase 3
77
Quadrivalent human papillomavirus vaccine on-time administration + Quadrivalent human papillomavirus vaccine delayed administrationMerckPre-clinical
23
GardasilMerckApproved
85
GardasilMerckPhase 2
52
9vHPV VaccineMerckPhase 3
77
9vHPV Vaccine + mRNA-1273 VaccineMerckPhase 3
77
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant VaccineMerckPhase 3
77
V503 + GARDASILMerckPhase 3
77
9vHPV VaccineMerckPhase 3
77
Gardasil vaccineMerckPre-clinical
23
V503MerckPhase 3
77
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) + PlaceboMerckPhase 3
77
V503 Vaccine + REPEVAX™ (Concomitant) + REPEVAX™ (Non-concomitant)MerckPhase 3
77
9vHPV vaccineMerckPhase 3
77
Gardasil™ + PlaceboMerckPhase 3
77
V503 + GardasilMerckPhase 3
77

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85